Designing peptides to block cancer-related protein interactions
Computationally designing peptides to interfere with p53-MDM2 and p53-sirtuin interaction
This study is looking for new ways to fight cancer by developing special tiny proteins that can block harmful interactions between important cancer-related proteins, which could help create better treatments for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project ID | NIH-10439131 on NIH RePORTER |
What this research studies
This research focuses on creating peptide inhibitors that can specifically bind to certain proteins involved in cancer, particularly the p53 protein and its interactions with MDM2 and SIRT1. By using advanced computational techniques like molecular docking and machine learning, the researchers aim to identify and optimize peptides that can effectively disrupt these protein interactions. This could potentially lead to new therapeutic options for cancer treatment by targeting the mechanisms that allow tumors to grow and evade the body's defenses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancers that involve the p53 protein and its interactions.
Not a fit: Patients with cancers unrelated to p53 or those who do not have the specific binding interactions targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that improve outcomes for cancer patients by targeting critical protein interactions involved in tumor growth.
How similar studies have performed: Previous research has shown promise in using peptide inhibitors to target protein interactions in cancer, indicating that this approach has potential for success.
Where this research is happening
Charlotte, United States
- University of North Carolina Charlotte — Charlotte, United States (Active)
Researchers
- Principal investigator: Jacobs, Donald — University of North Carolina Charlotte
- Study coordinator: Jacobs, Donald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.